Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma" [Biochem. Pharmacol. 214 (2023) 115678].
Coccè V, Bonelli M, Monica S, Alfieri R, Doneda L, Martegani E, Alessandri G, Lagrasta CA, Giannì A, Sordi V, Petrella F, Roncoroni L, Paino F, Pessina A. Coccè V, et al. Among authors: bonelli m. Biochem Pharmacol. 2024 Nov 28;231:116653. doi: 10.1016/j.bcp.2024.116653. Online ahead of print. Biochem Pharmacol. 2024. PMID: 39612648 No abstract available.
Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency : A prospective controlled open-label trial.
Vossen MG, Kartnig F, Mrak D, Simader E, Stiasny K, Kain R, Perkmann T, Haslacher H, Aberle JH, Heinz LX, Sieghart D, Burgmann H, Aletaha D, Scheinecker C, Bonelli M, Göschl L. Vossen MG, et al. Among authors: bonelli m. Wien Klin Wochenschr. 2024 Nov;136(21-22):598-607. doi: 10.1007/s00508-024-02459-6. Epub 2024 Oct 24. Wien Klin Wochenschr. 2024. PMID: 39446203 Free PMC article. Clinical Trial.
Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive Cancers.
De Forni D, Poddesu B, Cugia G, Bonelli M, Galetti M, Petronini P, Lagacé L, Chafouleas J, Lori F. De Forni D, et al. Among authors: bonelli m. Curr Med Chem. 2024 Sep 2. doi: 10.2174/0109298673298434240821101457. Online ahead of print. Curr Med Chem. 2024. PMID: 39225211
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
Fumarola C, La Monica S, Bonelli M, Zoppi S, Alfieri R, Galetti M, Gnetti L, Campanini N, Pozzi G, Cavazzoni A, Mazzaschi G, Silini EM, Buti S, Petronini PG. Fumarola C, et al. Among authors: bonelli m. Biochem Pharmacol. 2024 Aug;226:116397. doi: 10.1016/j.bcp.2024.116397. Epub 2024 Jun 27. Biochem Pharmacol. 2024. PMID: 38944394 Free article.
FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study.
Kastrati K, Nakuz TS, Kulterer OC, Geßl I, Simader E, Mrak D, Bonelli M, Kiener HP, Prayer F, Prosch H, Aletaha D, Langsteger W, Traub-Weidinger T, Blüml S, Lechner-Radner H, Hacker M, Mandl P. Kastrati K, et al. Among authors: bonelli m. EClinicalMedicine. 2024 Apr 10;72:102598. doi: 10.1016/j.eclinm.2024.102598. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38633577 Free PMC article.
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines.
Eltayeb K, Alfieri R, Fumarola C, Bonelli M, Galetti M, Cavazzoni A, Digiacomo G, Galvani F, Vacondio F, Lodola A, Mor M, Minari R, Tiseo M, La Monica S, Giorgio Petronini P. Eltayeb K, et al. Among authors: bonelli m. Biochem Pharmacol. 2024 Oct;228:116161. doi: 10.1016/j.bcp.2024.116161. Epub 2024 Mar 24. Biochem Pharmacol. 2024. PMID: 38522556 Free article.
280 results